CCM
TRML

CAAS Capital Management’s Tourmaline Bio TRML Stock Holding History

CAAS Capital Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,018
Closed -$92K – 914
2022
Q4 		$92K Sell
9,018
-20,753
-70% -$333K 0.01% 668
2022
Q3 		$783K Buy
+29,771
New +$1.08M 0.04% 415
2021
Q4 		– Sell
-1,249
Closed -$169K – 1050
2021
Q3 		$169K Sell
1,249
-7,751
-86% -$1.06M ﹤0.01% 750
2021
Q2 		$1.32M Buy
+9,000
New +$1.38M 0.02% 485

Other funds holding TRML

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

CAAS Capital Management's TRML Position: Q1 2023 in Review

CAAS Capital Management sold out of Tourmaline Bio (TRML) in Q1 2023, closing a stake of 9,018 shares — an estimated $92K sold.

CAAS Capital Management first reported a position in TRML in Q2 2021 and held it in 4 quarters. The position peaked at $1.32M in Q2 2021. 54 funds tracked by Wall St. Rank hold TRML as of Q1 2023.

  • CAAS Capital Management reported no remaining Tourmaline Bio position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 9,018 Tourmaline Bio shares in Q1 2023, an estimated $92K.
  • CAAS Capital Management first reported a position in Tourmaline Bio in Q2 2021 and held it in 4 quarters.
  • CAAS Capital Management's Tourmaline Bio position peaked at $1.32M in Q2 2021.
  • 54 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.